# Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

> **NCT06056570** · PHASE1,PHASE2 · COMPLETED · sponsor: **Urica Therapeutics Inc.** · enrollment: 20 (actual)

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** dontinurad
- **DRUG:** dotinurad + allopurinol
- **DRUG:** allopurinol

## Key facts

- **NCT ID:** NCT06056570
- **Lead sponsor:** Urica Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-04
- **Primary completion:** 2024-06-27
- **Final completion:** 2024-07-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056570, "Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06056570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*